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MicroRNAs (miRNAs) that regulate mRNA stability have been linked to amyloid
production, tau phosphorylation, and inflammation in Alzheimer’s disease (AD). However,
whether cerebral miRNA networks are dysregulated during the earliest stages of AD
remains underexplored. We performed miRNA expression analysis using frontal cortex
tissue harvested from subjects who died with a clinical diagnosis of no cognitive
impairment (NCI), amnestic mild cognitive impairment (aMCI, a putative prodromal
AD stage), or mild AD. Analysis revealed that the miRNA clusters miR-212/132
and miR-23a/23b were down-regulated in the frontal cortex of aMCI subjects. Both
miR-212/132 and miR23a/b are predicted to destabilize the message for sirtuin 1 (sirt1);
hence, down-regulation of either miR-212/132 or miR-23a/b in frontal cortex should
promote sirt1 mRNA expression in this region. qPCR studies revealed that frontal cortex
levels of sirt1 were increased in aMCI. Given the ability of frontal cortex to respond to the
onset of dementia by neuronal reorganization, these data suggest that miRNA-mediated
up-regulation of the sirt1 pathway represents a compensatory response to the onset of
the disease. By contrast, qPCR analysis of inferior temporal cortex, an area affected
early in the progression of AD, showed no changes in miR-212/132, miR-23a/b,
or sirt1 transcripts in the same aMCI subjects. In vitro mechanistic studies showed
that coordinated down-regulation of miR-212 and miR-23a increased sirt1 protein
expression and provided neuroprotection from β-amyloid toxicity in human neuronal
cells. Taken together, these data suggest a novel miRNA-mediated neuroprotective
pathway activated during the progression of AD that may be amenable to therapeutic
manipulation.
Keywords: Alzheimer’s disease, mild cognitive impairment, frontal cortex, microRNAs, sirtuin 1, miR-23a, miR-212,
gene expression regulation
INTRODUCTION
Progress in slowing the course of Alzheimer’s disease (AD) has been confounded by a lack of
disease modifying therapeutics. Given the vast complexity of this multisystem disorder, therapeutic
development will likely depend on a deeper understanding of the intricate molecular mechanisms
that regulate the maintenance and survival of selectively vulnerable neuronal populations during
disease progression. In this regard, the presence of small non-coding microRNAs (miRNAs)
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that negatively regulate mRNA stability (Lagos-Quintana et al.,
2001) presents an underexplored mechanism for fine-tuning
gene expression within complex cellular networks, which likely
plays a pivotal role in the balance between health and disease
(Nelson et al., 2008; Hébert and De Strooper, 2009). Select
miRNAs regulate diverse brain functions including neurogenesis
and differentiation, synaptic plasticity, and energy metabolism
(Schratt et al., 2006; Aschrafi et al., 2008; Fineberg et al., 2009;
Rajasethupathy et al., 2009). This widespread influence ofmiRNA
regulation on neuronal physiology suggests that perturbations
in miRNA function could be involved in the pathogenesis of
complex neurodegenerative disorders including AD (Nelson
et al., 2008; Hébert and De Strooper, 2009). Indeed, AD brains
display altered expression of several miRNAs that regulate β-
secretase BACE1, a key enzyme involved in the generation of
amyloid-β (Aβ) plaque pathology (Hébert et al., 2008; Wang
et al., 2008). In addition, miRNA dysregulation has been linked
to tau phosphorylation (Hébert et al., 2010; Absalon et al.,
2013; Banzhaf-Strathmann et al., 2014) and pro-inflammatory
activity (Cui et al., 2010; Lukiw et al., 2010; Li et al., 2012).
However, whether miRNA networks are dysregulated in the
brains of people in the putative prodromal stages of AD such as
amnestic mild cognitive impairment (aMCI) (Yaffe et al., 2006;
Albert et al., 2011) and the extent to which these changes have
physiologic consequences for the onset of AD remain unclear. To
begin to address these knowledge gaps, we performed microarray
and quantitative PCR (qPCR) studies to compare the levels of
miRNAs isolated from frontal cortex (Brodmann area 10) and
inferior temporal cortex (Brodmann area 20) tissue obtained
postmortem from people who died with a clinical diagnosis
of no cognitive impairment (NCI), aMCI, or AD. We report
that two families of miRNAs, miR-212/132 and miR-23a/b, were
down-regulated in frontal cortex in aMCI and AD compared
to NCI, yet remained stable in inferior temporal cortex. Down-
regulation of either miRNA family was predicted to up-regulate
the deacetylase sirtuin 1 (sirt1), which is involved in mediating
protective neuronal cell stress responses (Brunet et al., 2004; Qin
et al., 2006; Bonda et al., 2011). Sirt1 mRNA levels were higher in
frontal cortex of aMCI subjects but stable in inferior temporal
cortex, suggesting a link between miR-212/132 and miR-23a/b
down-regulation and reduced transcriptional repression of sirt1
target mRNA. Experimental down-regulation of miR-212 and
miR-23a in cultured neurons up-regulated sirt1 and provided
neuroprotection against Aβ toxicity. Given the relatively delayed
involvement of frontal cortex in AD pathogenesis and the ability
of this region to respond to the onset of dementia by neuronal
reorganization (DeKosky et al., 2002; Counts et al., 2006; Bell
et al., 2007; Williams et al., 2009; Bossers et al., 2010), these data
suggest that miRNA-mediated up-regulation of sirt1 is a novel
neuroprotective pathway activated during prodromal AD.
MATERIALS AND METHODS
Subjects
This study was exempt from IRB approval following guidelines
for using de-identified postmortem tissue administrated by the
Rush University Medical Center. Frontal and inferior temporal
cortex tissue was obtained postmortem from 32 participants in
the Rush Religious Orders Study (Bennett et al., 2002) who were
clinically diagnosed within a year of death with NCI (n = 12),
aMCI (n = 10), or AD (n = 10; see Table 1). Details of
clinical evaluations and diagnostic criteria have been previously
published (Mufson et al., 1999; Counts et al., 2006; Ginsberg
et al., 2010). In addition to an annual clinical evaluation, subjects
were administered the Mini Mental State Exam (MMSE) and
a battery of 19 neuropsychological tests referable to multiple
cognitive domains (e.g., episodic memory, perceptual speed,
Mufson et al., 1999). A Global Cognitive Score (GCS), consisting
of a composite z-score calculated from this test battery, was
determined for each participant (Bennett et al., 2002). The
MCI population was defined as subjects who exhibited cognitive
impairment on neuropsychological testing but who did not
meet the clinical criteria for AD recommended by the joint
working group of the National Institute of Neurologic and
Communicative Disorders and Stroke/AD and Related Disorders
Association (NINCDS/ADRDA) (McKhann et al., 1984; Bennett
et al., 2002). The aMCI diagnosis is based on impairments in
episodic memory (Yaffe et al., 2006; Albert et al., 2011). These
criteria are compatible with those used by experts in the field
to describe subjects who are not cognitively normal but do not
meet established criteria for dementia (Petersen et al., 2001).
“Other dementia” (OD) neurologic controls (n = 5) used in
the analysis included three multi-infarct dementia and two Lewy
body dementia cases.
Tissue samples were accrued as previously reported (Mufson
et al., 1999; Counts et al., 2006; Ginsberg et al., 2010). At
autopsy, tissue from one hemisphere was immersion-fixed in
4% paraformaldehyde in 0.1M phosphate buffer, pH 7.2 for
24–72 h at 4◦C. Tissue slabs from the opposite hemisphere
were frozen at −80◦C prior to biochemical analysis. Series
of fixed tissue sections were prepared for neuropathological
evaluation including visualization and quantitation of neocortical
and hippocampal amyloid plaques and neurofibrillary tangles
(NFTs) using antibodies directed against Aβ peptide (Aβ; 4 G8,
Covance), tau (PHF1, a gift fromDr. Peter Davies) (Mufson et al.,
1999; Bennett et al., 2002) as well as thioflavine-S histochemistry
and a modified Bielschowsky silver stain. Additional sections
were stained for Lewy bodies using antibodies directed
against ubiquitin and α-synuclein. Exclusion criteria included
argyrophilic grain disease, frontotemporal dementia, Lewy body
disease, mixed dementias, Parkinson’s disease, and stroke. A
board certified neuropathologist blinded to the clinical diagnosis
performed the neuropathological evaluation. Neuropathological
criteria were based on NIA-Reagan, CERAD, and Braak staging
(Braak and Braak, 1991; Mirra et al., 1991; Hyman et al., 2012).
Amyloid burden and apolipoprotein E (ApoE) genotype were
determined for each case as described previously (Mufson et al.,
1999; Bennett et al., 2002).
miRNA Expression Profiling
A pilot miRNA microarray screen (Exiqon miRCURY LNA
microarray v.11, ∼1360 array features including synthetic spike-
in miRNA controls) was performed using RNA derived from
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TABLE 1 | Clinical, demographic, and neuropathological characteristics by diagnosis category.
Clinical Diagnosis
NCI
(N = 12)
aMCI
(N = 10)
AD
(N = 10)
P-value Pair-wise
comparison
Age (years) at death:
Mean ± SD
(Range)
83.0 ± 5.9
(67–92)
82.9 ± 4.9
(72–90)
88.6 ± 7.0
(76–97)
0.3a –
Number (%) of males: 6 (50%) 5 (50%) 4 (40%) 0.4b –
Years of education:
Mean ± SD
(Range)
16.8 ± 3.4
(12–20)
18.8 ± 2.7
(12–22)
18.2 ± 3.4
(15–23)
1.0a –
Number (%) with ApoE ε4 allele:
MMSE:
Mean ± SD
(Range)
0 3 (33%) 4 (40%) 0.007b NCI < AD
28.3 ± 1.7
(26–30)
28.0 ± 1.3
(26–30)
17.5 ± 8.1
(7–28)
<0.001a (NCI, MCI) > AD
Global cognitive score:
Mean ± SD
(Range)
0.06 ± 0.3
(−0.3–0.7)
−0.03±0.4
(−0.6–0.2)
−1.3± 0.8
(−2.5–0.1)
<0.0001a (NCI, MCI) > AD
Postmortem interval (hours):
Mean ± SD
(Range)
5.7 ± 2.4
(3.0–12.4)
5.8 ± 3.1
(2.0–10.6)
4.8 ± 3.2
(1.5–12.3)
0.5a –
Distribution of Braak scores:
0
I/II
III/IV
V/VI
0
5
7
0
0
4
5
1
0
1
3
6
<0.001a (NCI, MCI) < AD
NIA Reagan diagnosis:
No AD
Low
Intermediate
High
0
7
3
0
0
5
5
0
0
1
4
5
<0.001a (NCI, MCI) < AD
CERAD diagnosis:
No AD
Possible
Probable
Definite
3
2
4
1
4
3
3
0
0
0
5
5
0.008a (NCI, MCI) < AD
aKruskal-Wallis test, with Bonferroni correction for multiple comparisons.
bFisher’s exact test, with Bonferroni correction for multiple comparisons.
postmortem frozen frontal cortex tissue from three NCI [age =
86.7 ± 1.5 (mean ± S.D.) years, MMSE = 29.7 ± 0.6,
PMI= 5.2± 1.5 h] and three AD (age = 87.7 ± 1.5, MMSE =
21.7 ± 2.5, PMI = 5.2 ± 1.7) subjects. Approximately 30% of
the miRNAs on the array were proprietary and not available
for analysis in public databases. Based upon the microarray
pilot data, we performed qPCR validation for select transcripts
using frozen frontal cortex and temporal cortex from each
of the NCI, aMCI, AD, and OD neurologic control cases
collected for the full study. Total RNA was extracted (miRvana,
Ambion) and RNA integrity and concentration was verified using
Bioanalysis (Agilent). Samples were assayed on a real-time PCR
cycler (7900HT, Applied Biosystems) in 96-well optical plates as
described previously (Counts et al., 2007; Ginsberg, 2008; Alldred
et al., 2009). Target miRNAs of interest as well as the RNU48
artificial normalization control were amplified using specific
Taqman hydrolysis probe sets (Applied Biosystems). In addition,
Taqman probe sets specific for sirt1 and control glyceraldehyde
3-phosphate dehydrogenase were used to quantify sirt1 transcript
levels in the same samples. The ddCT method was employed to
determine relative expression levels of each amplicon (Counts
et al., 2007; Ginsberg, 2008; Alldred et al., 2009). Variance
component analyses revealed relatively low levels of within-case
variability, and the average value of the triplicate qPCR products
from each case was used in subsequent analyses.
Dual in Situ
Hybridization/Immunohistochemical
Localization of miR-23a and Sirt1
In situ hybridization to detect miR-23a was performed on
10µm, cryostat-sectioned samples of frozen frontal cortex
using a digoxin (DIG)-labeled hsa-miR-23a probe (Exiqon),
adapting the protocol of Doné and Beltcheva (2014). Briefly,
tissue sections were fixed in 10% neutral buffered formalin
overnight at room temperature (RT). The next day, sections
were treated with 20µg/mL proteinase K for 10min at 37◦C
followed by hybridization with 400 nmol hsa-miR-23a probe
for 1 h at 55◦C. The sections were then blocked with 2%
sheep serum/1% bovine serum albumin for 15min at RT
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followed by incubation with alkaline phosphatase-conjugated
sheep anti-DIG Fab fragments (1:500, Roche) for 1 h at
RT. The sections were then incubated with the alkaline
phosphatase substrates NBT (nitro blue tetrazolium)/BCIP (5-
bromo-4-chloro-3-indolyl-phosphate; Roche) for 2 h at 30◦C
revealing a dark purple reaction product. Following miR-23a
visualization, the sections were incubated overnight at 4◦C
with a rabbit anti-sirt1 monoclonal antibody (1:100, Origene)
in Tris-buffered saline (TBS, pH 7.4)/0.25% Triton X-100/1%
normal goat serum. Following TBS rinses, the sections were
incubated with horseradish peroxidase-conjugated goat anti-
rabbit secondary antiserum (Vector Laboratories) for 1 h at
RT. Sirt1 labeling was accomplished by serial incubations
in ABC peroxidase reagent (Vector Laboratories) and 3,
3′diaminobenzidine tetrahydrochloride hydrate at RT to reveal
a brown reaction product.
Neuronal Cell Culture
hNT neuronal cultures were derived from the human
teratocarcinoma NT2 cell line (a gift from Dr. Virginia Lee,
Univ. Penn) (Andrews et al., 1984; Counts and Mufson, 2010).
NT2 cells were maintained in OptiMem (Invitrogen) with
5% fetal bovine serum (FBS). For differentiation, cells were
seeded at 25,000/cm2 into T75 flasks in 1:1 DMEM/F-12 media
(Invitrogen)/10% FBS, treated twice a week with 10µM all-trans
retinoic acid (Sigma) for 4 weeks and then seeded to new T75
flasks at 650,000/cm2 and treated with the mitotic inhibitors
cytosine arabinoside (1µM) and fluorodeoxyuridine (10µM,
Sigma) for 2 weeks. This resulted in a layer of phase-bright,
post-mitotic neuronal cells loosely attached atop a monolayer
of non-neuronal cells. Neuronal enrichment was achieved by
gently trypsinizing the top neuronal layer and replating at
125,000/cm2 onto 2% Matrigel (BD Biosciences) and 10µM
poly-D-lysine (Sigma)-coated black-walled 96 well plates (cell
viability) or 60mm dishes (western blotting) (BD Biosciences) in
1:1 DMEM/F-12 media/10% FBS (Counts and Mufson, 2010).
miRNA Inhibition and Functional Validation
hNT cultures were transfected with small miRNA inhibitors
(miRCURY LNA inhibitors, Exiqon) specific for miR-212, miR-
132, miR-23a, miR-23b, or an inhibitor negative control sequence
(Exiqon) (n = 8/treatment group in three independent
experiments). hNT neurons were plated at 20K/cm2 and
incubated with 50 nM inhibitor/1% Lipofectamine RNAiMAX
(Life Technologies) in OptiMem for 18 h, then exchanged into 1:1
DMEM/F-12 media/10% FBS for 36 h prior to experimentation.
Quantitative Western Blotting
hNT neurons were harvested 36 h post-transfection and
separated into nuclear and cytosolic fractions (NE-PER,
Pierce) for quantitative immunoblotting. Nuclear proteins were
solubilized in loading buffer and separated by SDS-PAGE,
transferred to Immobilon-P membranes (Millipore), blocked
in Tris buffered saline (pH 7.4) containing 0.1% Tween-20
and 2% nonfat milk, and then incubated overnight at 4◦C
with rabbit polyclonal antiserum to sirt1 (1:500; Chemicon)
and a mouse monoclonal antibody to lamin A (1:500, Abcam)
as a loading control for the nuclear fraction. Blots were then
incubated for 1 h with horseradish peroxidase-conjugated goat
anti-rabbit (Bio-Rad; 1:5000) and anti-mouse (1:8000; Pierce,
IL) IgG secondary antibodies and reactivity was quantified
using Kodak 1D image analysis software (Perkin-Elmer).
Each sample was analyzed on three different Western blots in
independent experiments. Signals for sirt1 were normalized
to lamin A for quantitative analysis (Counts et al., 2004,
2006).
Amyloid Toxicity Experiments
Following miRNA inhibitor or control transfections,
differentiated hNT neurons were challenged with 10µM
Aβ1−42 for 48 h in the presence or absence of the sirt1-specific
inhibitor EX527 (100 nM, Tocris). Aβ1−42 was dissolved in
DMSO and pre-aggregated for 16 h at 37◦C. Western blotting
revealed an accumulation of SDS-soluble immunoreactive
material migrating at ∼40–48 kDa reminiscent of oligomeric
amyloid (Walsh et al., 1999). Neuronal viability was determined
by propidium iodide (PI) retention (Counts and Mufson, 2010).
Statistical Analysis
miRNA levels quantified by qPCR were compared among the
NCI, aMCI, AD, and OD neurologic controls via One-way
ANOVA with Bonferroni post-hoc testing. The relationship
between specific miRNA and mRNA levels was assessed by
Spearman rank correlations. Quantitative Western blotting data
of control and miR-treated samples were analyzed by unpaired t-
tests. Finally, cell death comparisons in the different cell culture
treatment groups were assessed by One-way ANOVA with
Bonferroni post-hoc testing. The level of statistical significance
was set at α = 0.05 (two-tailed).
RESULTS
Subject Demographics
The clinical diagnostic groups did not differ by age, gender, years
of education, or postmortem interval (Table 1). There were more
subjects with an ApoE 4 allele in the aMCI (33%) and AD (44%)
groups than in the NCI group (0%). AD cases had significantly
lower MMSE scores compared to both aMCI and NCI cases (p <
0.001), whereas the latter two groups did not differ statistically
(Table 1). GCS z-scores were significantly lower in AD compared
to the NCI and aMCI groups (p < 0.0001). Subjects in
the different clinical diagnostic groups displayed considerable
heterogeneity with respect to pathological diagnostic criteria.
Neuropathological examination revealed that 58% of NCI, 60% of
aMCI, and 90% of AD cases were classified as Braak stages III–VI.
Using NIA-Reagan criteria, 25% of NCI, 50% of aMCI, and 90%
of AD cases were classified as intermediate to high likelihood of
AD (Table 1). For CERAD diagnosis, 42% of NCI, 30% of aMCI,
and 100% of AD cases received a diagnosis of probable/definite
AD. Statistical analysis revealed that the AD group displayed
significantly higher pathology than the NCI and aMCI groups
based on Braak (p < 0.001), NIA-Reagan (p < 0.001) and
CERAD (p = 0.008) diagnosis.
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TABLE 2 | Top 100 miRNAs dysregulated in AD compared to NCI frontal
cortex.
Annotation P-value Average AD vs. NCI
NCI AD 1LMR Fold change
hsa-miR-1285 5.92E-04 0.04 −0.21 −0.25 0.84
hsa-miR-1296 2.00E-03 −0.09 −0.33 −0.24 0.85
hsa-miR-668 5.48E-03 −0.06 −0.57 −0.51 0.70
hsa-miR-551b* 6.07E-03 −0.45 −0.01 0.44 1.36
hsa-miR-1826 6.49E-03 −0.11 −0.53 −0.42 0.75
hsa-miR-518e* 7.48E-03 −0.44 0.15 0.59 1.50
hsa-miR-132 9.07E-03 0.53 −0.22 −0.74 0.60
hsa-miR-525-5p 1.08E-02 −0.09 0.15 0.24 1.18
hsa-miR-135b 1.40E-02 0.45 0.17 −0.29 0.82
hsa-miR-671-5p 2.23E-02 −0.24 0.00 0.24 1.18
hsa-miR-498 2.68E-02 −0.23 0.29 0.51 1.43
hsa-miR-423-3p 2.76E-02 0.05 −0.17 −0.22 0.86
hsa-miR-886-3p 2.95E-02 0.32 −1.62 −1.94 0.26
hsa-miR-518a-5p 3.76E-02 −0.29 0.07 0.36 1.29
hsa-miR-204 3.97E-02 0.41 0.19 −0.22 0.86
hsa-miR-886-5p 4.21E-02 0.02 −1.49 −1.50 0.35
hsa-miR-132* 4.25E-02 0.24 −0.67 −0.91 0.53
hsa-miR-129* 4.38E-02 0.20 −0.36 −0.56 0.68
hsa-miR-382 4.08E-02 0.16 −0.03 −0.19 0.88
hsa-miR-921 5.35E-02 −0.58 −0.13 0.45 1.36
hsa-miR-140-5p 5.67E-02 0.33 −0.18 −0.51 0.70
hsa-miR-330-5p 5.87E-02 0.38 0.23 −0.15 0.90
hsa-miR-510 6.01E-02 −0.17 0.12 0.28 1.22
hsa-miR-491-3p 6.15E-02 0.23 −0.35 −0.57 0.67
hsa-miR-320a 7.03E-02 0.29 −0.27 −0.56 0.68
hsa-miR-877 7.05E-02 −0.11 0.17 0.28 1.22
hsa-miR-320b 7.07E-02 0.29 −0.26 −0.55 0.68
hsa-miR-1252 7.13E-02 −0.43 0.10 0.53 1.44
hsa-miR-30e 7.40E-02 0.24 −0.31 −0.55 0.68
hsa-miR-129-3p 7.40E-02 0.21 −0.45 −0.65 0.64
hsa-miR-149 7.43E-02 0.14 −0.26 −0.40 0.76
hsa-miR-25* 7.49E-02 −0.21 0.15 0.36 1.28
hsa-miR-149* 7.57E-02 −0.02 0.36 0.38 1.30
hsa-miR-483-5p 7.63E-02 −0.29 0.18 0.47 1.39
hsa-miR-630 7.94E-02 −0.16 0.30 0.46 1.38
hsa-miR-1273 8.07E-02 −0.45 0.14 0.59 1.50
hsa-miR-1264 8.34E-02 0.20 −0.12 −0.32 0.80
hsa-let-7a* 8.46E-02 0.21 −0.10 −0.31 0.81
hsa-miR-505* 8.53E-02 −0.20 0.27 0.47 1.38
hsa-miR-377* 8.62E-02 0.00 0.15 0.15 1.11
hsa-miR-21 8.77E-02 0.39 −0.69 −1.08 0.47
hsa-miR-126 8.81E-02 0.14 −0.22 −0.36 0.78
hsa-miR-625 9.22E-02 −0.20 0.11 0.31 1.24
hsa-miR-320d 9.33E-02 0.17 −0.21 −0.39 0.77
hsa-miR-29b-2* 9.40E-02 −0.01 −0.33 −0.33 0.80
hsa-miR-29c* 9.41E-02 0.13 −0.15 −0.27 0.83
hsa-miR-30a 9.58E-02 0.14 −0.28 −0.41 0.75
hsa-miR-1265 9.70E-02 0.20 −0.03 −0.23 0.85
(Continued)
TABLE 2 | Continued
Annotation P-value Average AD vs. NCI
NCI AD 1LMR Fold change
hsa-miR-135a 1.00E-01 0.51 −0.04 −0.54 0.69
hsa-let-7i 1.04E-01 0.15 −0.33 −0.48 0.72
hsa-miR-589 1.04E-01 −0.14 −0.46 −0.32 0.80
hsa-miR-1201 1.06E-01 −0.20 −0.57 −0.37 0.78
hsa-miR-1259 1.06E-01 0.12 −0.22 −0.34 0.79
hsa-miR-720 1.07E-01 0.18 −0.24 −0.42 0.75
hsa-miR-34b 1.09E-01 0.10 −0.21 −0.32 0.80
hsa-let-7c 1.09E-01 0.19 −0.27 −0.46 0.73
hsa-miR-320c 1.09E-01 0.23 −0.20 −0.43 0.74
hsa-miR-583 1.12E-01 −0.35 0.10 0.46 1.37
hsa-miR-206 1.12E-01 −0.07 0.25 0.32 1.24
hsa-miR-23a 1.12E-01 0.03 −0.44 −0.47 0.62
hsa-miR-181c 1.12E-01 −0.08 −0.44 −0.36 0.78
hsa-miR-769-5p 1.16E-01 0.11 −0.30 −0.41 0.75
hsa-miR-181b 1.17E-01 0.47 −0.46 −0.93 0.53
hsa-miR-1827 1.19E-01 −0.26 0.29 0.55 1.46
hsa-miR-1253 1.20E-01 −0.58 −0.32 0.26 1.19
hsa-miR-301a 1.20E-01 0.16 −0.38 −0.54 0.69
hsa-miR-184 1.21E-01 −0.17 0.15 0.32 1.25
hsa-miR-140-3p 1.21E-01 0.14 −0.46 −0.61 0.66
hsa-miR-33a 1.21E-01 0.31 −0.27 −0.58 0.67
hsa-miR-485-3p 1.22E-01 −0.18 0.16 0.34 1.26
hsa-miR-1274b 1.22E-01 0.21 −0.36 −0.56 0.68
hsa-miR-181a* 1.22E-01 0.07 −0.46 −0.53 0.69
hsa-miR-516a-5p 1.23E-01 −0.42 0.02 0.44 1.36
hsa-miR-30d 1.24E-01 0.24 −0.11 −0.35 0.78
hsa-miR-150 1.25E-01 −0.28 0.38 0.66 1.58
hsa-miR-874 1.25E-01 −0.03 −0.24 −0.20 0.87
hsa-miR-339-5p 1.27E-01 −0.03 −0.48 −0.45 0.73
hsa-miR-146b-5p 1.28E-01 0.29 −0.26 −0.55 0.68
hsa-let-7g 1.28E-01 0.10 −0.41 −0.50 0.70
hsa-miR-142-3p 1.28E-01 0.56 0.04 −0.51 0.70
hsa-miR-212 1.29E-01 −0.10 −0.53 −0.44 0.64
hsa-miR-518d-5p 1.30E-01 −0.12 0.08 0.19 1.14
hsa-miR-433 1.32E-01 0.03 −0.14 −0.18 0.89
hsa-miR-200b* 1.34E-01 −0.16 0.20 0.36 1.28
hsa-miR-491-5p 1.34E-01 0.02 −0.31 −0.32 0.80
hsa-miR-24 1.35E-01 0.16 −0.39 −0.54 0.69
hsa-miR-193b* 1.38E-01 −0.26 0.19 0.46 1.37
hsa-miR-130b* 1.38E-01 −0.13 0.18 0.31 1.24
hsa-miR-30c 1.40E-01 0.14 −0.22 −0.36 0.78
hsa-miR-23b 1.41E-01 0.13 −0.53 −0.66 0.63
hsa-miR-106b 1.42E-01 0.30 −0.32 −0.62 0.65
hsa-let-7b 1.42E-01 0.30 −0.14 −0.45 0.73
hsa-let-7d 1.43E-01 0.17 −0.43 −0.60 0.66
hsa-miR-647 1.43E-01 −0.29 0.04 0.33 1.26
hsa-miR-181a 1.43E-01 0.42 −0.95 −1.37 0.39
hsa-miR-130a 1.44E-01 0.16 −0.11 −0.28 0.82
*Star strand of miRNA.
Frontiers in Neuroscience | www.frontiersin.org 5 November 2015 | Volume 9 | Article 430
Weinberg et al. microRNA pathways in MCI
miRNA Expression Dynamics during the
Progression of AD
A small pilot miRNA microarray screen performed on RNA
isolated from frozen frontal cortex tissue from three NCI and
AD cases showed that the expression levels of 30 miRNAs
were significantly different between the two groups, along
with miRNAs that showed high but non-significant magnitudes
of expression change between the two groups. The top 100
miRNAs are listed in Table 2. We performed qPCR to measure
select miRNAs in frontal cortex across all groups examined.
Specifically, we tested the expression levels of 20 of the top
100 miRNAs based on significant differences, magnitude of
expression level difference and/or interest based on a literature
search (Cogswell et al., 2008; Hébert et al., 2013; Lau et al.,
2013; Wong et al., 2013) (Table 3). Of the 20 candidate
miRNAs evaluated, miR-498, and miR-150 were significantly up-
regulated in AD frontal cortex; miR-150 was up-regulated in
aMCI. Several miRNAs were also significantly down-regulated
in AD frontal cortex, including miR-886-3p, miR-132, miR-
21, miR-23a, miR-140-3p, miR-212, miR-23b, let-7d, and miR-
181a (Table 3). However, two distinct clusters of these miRNAs,
miR212/132, and miR 23a/23b, were also significantly down-
regulated by ∼50% in the frontal cortex of aMCI subjects
relative to NCI subjects (Table 3, Figures 1A,B). By contrast,
qPCR analysis of temporal cortex revealed that miR-212
and miR-132 expression levels were decreased only in the
AD group, whereas miR-23a and miR-23b were unchanged
across the clinical diagnostic groups (Table 4). Since miRNAs
negatively regulate transcript stability, down-regulation of the
TABLE 3 | qPCR analysis of select miRNAs in frontal cortex of NCI, aMCI,
and AD subjects.
miRNA aMCI fold 1 vs. NCI AD fold 1 vs. NCI
hsa-miR-668 0.87 0.85
hsa-miR-135b 0.76 0.84
hsa-miR-498 1.27 1.39*
hsa-miR-886-3p 0.85 0.51**
hsa-miR-132 0.58** 0.42**
hsa-miR-320a 0.98 0.91
hsa-miR-1252 1.17 1.14
hsa-miR-1273 1.03 1.22
hsa-miR-21 0.78 0.65*
hsa-miR-23a 0.53** 0.41**
hsa-miR-181b 0.88 0.93
hsa-miR-1827 1.27 1.21
hsa-miR-140-3p 0.85 0.62*
hsa-miR-33a 0.76 0.81
hsa-miR-150 1.43* 1.56**
hsa-miR-212 0.47** 0.41**
hsa-miR-23b 0.71* 0.62**
hsa-miR-106b 1.05 0.97
hsa-let-7d 0.73 0.66*
hsa-miR-181a 0.69 0.62*
*p < 0.05, **p < 0.01.
miR-212/132 and miR-23a/b clusters in frontal cortex would
be predicted to promote the stability of their target mRNAs in
aMCI. Given several lines of evidence that the frontal cortex
undergoes neuroplastic, presumably neuroprotective remodeling
in the face of mounting AD neuropathology during MCI
(DeKosky et al., 2002; Counts et al., 2006; Bell et al., 2007;
Williams et al., 2009; Bossers et al., 2010), we searched
the miRanda and miRbase prediction algorithm databases
(microRNA.org) for mRNA targets of these miRNAs that might
mediate potentially compensatory pathways to promote neuronal
viability. Surprisingly, all four miRNAs were predicted to target
sirt1, a histone deacetylase involved in mediating neuronal cell
stress responses (Brunet et al., 2004; Qin et al., 2006; Bonda
et al., 2011). To determine whether target sirt1 transcripts were
also differentially regulated in the frontal and temporal cortex
in aMCI, we performed qPCR analysis of sirt1 expression levels
in the same tissue samples used for miRNA analysis. This
analysis revealed that sirt1 mRNA levels were significantly up-
regulated by ∼40% in the frontal cortex of aMCI compared
to NCI and AD subjects (Figure 1C). By contrast, sirt1 levels
were stable in temporal cortex across the diagnostic groups
(Table 4). Furthermore, increased sirt1 mRNA expression was
significantly associated with decreased miR-212 levels frontal
cortex levels, but this association was not found in the temporal
cortex (Figure 2).
Localization of miR-23a and Sirt1 in the
Frontal Cortex
Dual miR-23a in situ hybridization and sirt1
immunohistochemistry revealed nuclear miR-23a labeling
in frontal cortex layer III neurons in tissue obtained from an
87 year-old female subject who died with a clinical diagnosis
of aMCI (Figure 3). Sirt1 protein immunoreactivity was found
primarily in the nucleus but also within the cytoplasm of the
same neurons, providing evidence that miR-23a has direct access
to its sirt1 target and that miR-directed sirt1 regulation in cortex
is neuronal in origin.
miR-212 and miR-23a Down-regulation
Increases Sirt1 Protein Expression in
Human Neuronal Cells
To determine the extent to which concomitant down-regulation
of miR-212/132 and miR-23a/b and up-regulation of sirt1
observed in aMCI frontal cortex represented a functionally
significant relationship, we treated human hNT neuronotypic
cells with specific inhibitors of these miRNAs and measured sirt1
protein expression. Interestingly, inhibition of miR-212, miR-
132, miR-23a, or miR-23b individually had no effect on sirt1
expression, but we found that concurrent inhibition of miR-
212 and miR-23a resulted in a significant ∼100% increase in
sirt1 (Figure 4), whereas co-inhibition of miR-132 and miR-
23a resulted in a ∼40% increase in sirt1 (p < 0.05, data
not shown). By contrast, miR-23b co-inhibition with miR-
212 or miR-132 had no effect on sirt1 expression (data not
shown).
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FIGURE 1 | Differential expression of miR-212, miR-23a, and sirt1 transcripts in the frontal cortex of aMCI subjects. qPCR analysis was performed on
frozen frontal cortex tissue samples harvested from NCI (n = 12), aMCI (n = 10), mild AD (n = 10), and other dementia (OD, n = 5) neurologic control subjects. Box
plots show that (A) miR-212 and (B) miR-23a were significantly down-regulated by ∼50% in aMCI and by ∼60% in AD. (C) Their predicted mRNA target sirt1 was
up-regulated by ∼40% in aMCI. miR expression levels were normalized to the human RNU48 control miRNA, whereas sirt1 mRNA was normalized to GAPDH for
quantitative analysis. **p < 0.01 via One-way ANOVA with Bonferroni correction for multiple comparisons.
TABLE 4 | qPCR analysis of select miRNAs and sirt1 mRNA in temporal
cortex of NCI, aMCI, and AD subjects.
Probe set aMCI fold 1 vs. NCI AD fold 1 vs. NCI
hsa-miR-212 0.96 0.63*
hsa-miR-132 0.88 0.65*
hsa-miR-23a 0.92 0.87
hsa-miR-23b 1.03 0.98
hsa-miR-150 1.32 1.47**
has-miR-668 0.95 1.01
sirt 1 mRNA 1.12 0.94
*p < 0.05, **p < 0.01.
miR-23a and miR-212 Down-regulation
Protects against Aβ1−42 Induced Cell Death
via Sirt1
To test whether miR-212 and miR-23a regulation of sirt1 results
in neuronal protection, hNT cells were treated with inhibitors of
either miRNA independently, or with inhibitors of both miRNAs
combined, followed by challenge with Aβ1−42, which has been
shown to induce cell death in these neuronal cells (Counts and
Mufson, 2010). Inhibition of both miRNAs was sufficient to
reduce Aβ1−42 induced cell death (Figure 5). This response was
blocked by co-administration with the sirt1 inhibitor EX527
(Figure 5), supporting the concept that miRNA regulation of
sirt1 expression is a viable neuroprotective pathway.
DISCUSSION
The discovery of miRNAs (Lagos-Quintana et al., 2001)
introduced a new layer of complexity to gene regulation, but
also afforded the opportunity to better understand the molecular
underpinnings of cellular function and dysfunction. This concept
has already been well-demonstrated in cancer research and the
potential therapeutic value of targeting miRNAs has been gaining
acceptance in that field (Ma and Weinberg, 2008). With respect
to neurodegenerative disorders such as AD, the presence of
miRNAs in the human brain and evidence for miRNA function
in a wide variety of complex neuronal processes, including
synaptic plasticity, suggests that miRNA regulation could have
immense implications not only for disease pathogenesis but
also for neuronal responses to progressive neurodegeneration
(Kosik, 2006). Prior studies show that miRNAs could impact
AD progression through several mechanisms. For instance,
postmortem human tissue studies in well-characterized cohorts
have shown decreased neocortical levels of miR-29a/b, miR-
9, and miR-107 in AD compared to control subjects, which
was associated with increased BACE1 mRNA expression and
Aβ generation (Hébert et al., 2008; Wang et al., 2008; Che
et al., 2014); in particular, miR-107 is downregulated very early
in the disease process (Wang et al., 2008). By contrast, miR-
15a is decreased in AD brain compared to healthy controls
and is implicated in tau hyperphosphorylation in vivo (Hébert
et al., 2010). Here, we show that mir-132/212 and miR-
23a/b are selectively down-regulated in the frontal cortex
Frontiers in Neuroscience | www.frontiersin.org 7 November 2015 | Volume 9 | Article 430
Weinberg et al. microRNA pathways in MCI
FIGURE 2 | Inverse relationship between miR-212 and sirt1 expression in the frontal cortex. Spearman rank correlations were performed to test for
relationships between miR-212 and sirt1 expression. Scatterplots show that lower miR-212 transcript expression was associated with higher sirt1 transcript
expression in (A) frontal cortex (r = −0.81, p < 0.0001), but not in (B) temporal cortex in the subjects examined.
FIGURE 3 | miR-23a and sirt1 co-localize in the nucleus of frontal
cortex layer III neurons. Dual in situ hybridization/immunohistochemistry of
miR-23a RNA and sirt1 protein expression was performed in frontal cortex of
an 87 year-old female subject who died with a clinical diagnosis of aMCI. (A)
Photomicrograph shows layer III neurons co-labeled with miR-23a labeling
(dark purple) and sirt1 (brown, arrows). Note that miR-23a appears localized to
the nucleus, whereas sirt1 labeling is nuclear but also with immunoreactivity in
the cytoplasm. (B) Dual miR-23a/sirt1 detection in the absence of sirt1 primary
antibody (anti-rabbit IgG only). (C) Dual miR-23a/sirt1 detection with control
scrambled miRNA probe. Scale bar = 30µm.
in subjects clinically diagnosed with aMCI and that these
alterations appear to be functionally linked to an up-regulation
of sirt-1 and sirt-1 mediated protective responses. This novel
finding adds to a growing literature on miRNA involvement
in AD pathophysiology. However, rather than implicating
another group of miRNAs in promoting neurodegeneration, our
data support the concept that innate neuronal compensatory
miRNA-mediated pathways are also activated in aMCI. A greater
understanding of these and other miRNA pathways functioning
during these putative prodromal stages of AD holds the promise
that these pathways could be harnessed pharmacologically for
drug development.
The miR-132/212 cluster has been implicated in several
neuronal pathways, including dendritic elaboration (Magill et al.,
2010) and learning and memory (Wang et al., 2013), and
is downregulated in AD neocortex (Cogswell et al., 2008;
Hébert et al., 2013; Lau et al., 2013; Wong et al., 2013). In
particular, Wong and colleagues have previously shown that the
miR-212/132 cluster is down-regulated in temporal cortex in AD,
and that inhibition of miR-212 and/or miR-132 expression can
induce apoptosis in primary neurons after 1 week in culture
via activation of a foxo3a-mediated cell death pathway (Wong
et al., 2013). In this regard, we replicated the finding that the
miR-212/132 cluster is down-regulated in the temporal cortex
in AD. However, we found no reductions in miR-212/132 in
this region in aMCI; miR-212/132 was down-regulated in aMCI
only in frontal cortex. In addition, in our hands experimental
inhibition of miR-212 and/or miR-132 had no effect on cell
survival of hNT neurons after 48 h in the absence of Aβ1−42.
However, co-inhibition of either miR-212 or miR-132 with
miR-23a conferred neuroprotection against Aβ1−42 in a sirt1-
dependent manner. These discrepancies are likely explained by
several factors. For instance, down-regulation of these miRNAs
may have different functional implications in the AD temporal
cortex, which displays a greater degree of degenerative changes
than the aMCI frontal cortex. Notably, we found that sirt1 up-
regulation in frontal cortex was confined to aMCI, suggesting
that other AD-related pathways prevent sirt1 activation as
the disease progresses. The down-regulation of miR-212/132
in aMCI frontal cortex may initially participate in protective
compensatory mechanisms, but with sustained reductions these
miRNAs may join a pathological cascade that promotes disease
progression through foxo3a. In this regard, sirt1 activity has
been shown to protect against foxo3a-mediated pro-apoptotic
pathways by the deacetylation of this transcription factor (Brunet
et al., 2004; Qin et al., 2008). Moreover, the differential roles
for this cluster may depend on target binding partners, since
miR-212/132 and miR-23a co-inhibition was required for sirt1
activation and neuroprotection. Hence, the activity of the miR-
212/132 cluster may be context dependent during the progression
of AD.
miR-23a/b has also been shown to be dysregulated in
the AD brain (Cogswell et al., 2008; Lau et al., 2013), yet
much less is known about this miRNA cluster in neuronal
function. However, like miR-212/132, miR-23a levels have been
inversely linked to apoptosis. In a recent report detailing
mechanisms for neuronal cell death in a model of traumatic
brain injury, in vitro studies revealed that miR-23a inhibition
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FIGURE 4 | Experimental down-regulation of miR-212 and miR-23a
increases sirt1 protein expression. Human hNT neuronotypic cells were
co-transfected with small inhibitors of miR-212 and 23a or scrambled negative
controls (CTL). Given the co-localization of miR-23a and sirt1 in the nucleus,
cells were harvested 36 h following transfection with the miRNA inhibitors or
controls and nuclear fractions were immunoblotted for detection of sirt1. (A) A
representative western shows that miR-212/23a co-repression resulted in an
increase in sirt1 immunoreactivity. (B) Quantitative analysis revealed that sirt1
levels were significantly increased by ∼100% in miR-212/23a
inhibitor-transfected cells compared to CTL-transfected cells. n = 6/group;
**p < 0.01 via Student’s unpaired test (two-tailed).
increased etoposide-induced cell death after 24 h in cortical
neurons via caspase activation (Sabirzhanov et al., 2014). By
contrast, we found that miR-23a inhibition alone had no effect
on Aβ-induced cell death after 48 h, yet was neuroprotective
in the presence of miR-212 by activating sirt1. Again, these
discordances are not incompatible, but suggest that miR-23a
has both pro-apoptotic and neuroprotective properties that
depend on specific miRNA binding partners and whether these
miRNAs are targeting pro-apoptotic factors such as caspases or,
as presently shown, factors such as sirt1 that promote neuronal
viability.
While the functional consequences of sirt1 up-regulation in
this paradigm are unclear, sirt1 deacetylase activity plays an
important role in regulating diverse cellular processes including
aging, inflammation, and stress resistance (Imai et al., 2000;
Brunet et al., 2004; North and Verdin, 2004; Herskovits and
Guarente, 2014). In the adult brain, sirt1 can also modulate
dendritic (Codocedo et al., 2012) and synaptic plasticity as
well as memory formation (Gao et al., 2010; Michán et al.,
2010). In addition to its importance during normal brain aging,
sirt1 may also confer protective properties in neurodegenerative
disorders such as AD (Qin et al., 2006, 2008; Min et al.,
2010). Experimentally, sirt1 can reduce both Aβ-induced
toxicity in neuronal cell lines (Conte et al., 2003; Han et al.,
2004) and amyloid plaque formation in AD transgenic mice
(Karuppagounder et al., 2009; Vingtdeux et al., 2010). Neuronal
sirt1 expression has also been linked to non-amyloidogenic
APP processing (Qin et al., 2006). Hence, we validated these
concepts by showing that miR212/132 and miR-23a-mediated
neuroprotection against Aβ is prevented by a sirt1-specific
inhibitor. Sirt1 has also been shown to ameliorate tangle-like
pathology in tau mutant mice (Kim et al., 2007; Min et al.,
2010), possibly by tau deacetylation that allows ubiquitin ligases
to target tau for degradation (Min et al., 2010; Cohen et al., 2011).
Hence, there are several mechanisms by which miR-212/132
and miR-23a co-regulation of sirt1 expression may promote
neuroprotection in the frontal cortex in aMCI. However, it is
FIGURE 5 | Experimental down-regulation of miR-212 and miR-23a
protects against Aβ1−42 in a sirt1-dependent manner. Human hNT
neuronotypic cells were co-transfected with small inhibitors of miR-212 and
23a or scrambled negative controls (CTL). Cells were then treated with 10µM
Aβ1−42 for 48 h in the presence or absence of 100 nM EX527, a sirt1-specific
inhibitor, followed by incubation with propidium iodide (PI) as an assay for cell
death. Bar graph shows that Aβ1−42 treatment resulted in significant cell
death that was significantly reduced by miR-212/23a co-repression. This
rescue effect was reversed by EX527, suggesting that the protective effects of
miR-212/23a co-repression was mediated by sirt1. n = 8/group; *p < 0.05 vs.
CTL; **p < 0.05 vs. Aβ1−42 via One-way ANOVA with Bonferroni correction for
multiple comparisons.
sirt1’s role in the regulation and maintenance of dendritic growth
(Codocedo et al., 2012) that could also play an important role
in frontal cortex plasticity responses in MCI. In this regard,
sirt1 knockout (KO) mice display reduced dendritic profiles
relative to wild-type mice (Michán et al., 2010). Furthermore,
overexpression of sirt1 can increase dendritic arborization, a
phenotype that renders neurons resistant to dendritic dystrophy
induced by Aβ (Codocedo et al., 2012). These data, taken together
with multiple lines of evidence for a paradoxical up-regulation of
synaptic elements within the frontal cortex during MCI (Counts
et al., 2006; Bell et al., 2007; Williams et al., 2009; Bossers et al.,
2010), suggest that sirt1 may mediate a synaptic remodeling
response to mounting pathology during the progression of AD.
In summary, our data suggest that the transition from
normal cognitive function in aging to a clinical diagnosis
of aMCI may involve the suppression of brain microRNA
networks such as miR212/132 and miR-23a. In the frontal
cortex, this may result in the induction of cellular survival
pathways including the stabilization of sirt1. Ultimately, as aMCI
progresses to AD, the robust sirt1 expression is lost in frontal
cortex, mimicking the situation seen in the temporal cortex.
Recent microarray data suggest that the pattern of expression
seen in sirt1 is also seen in other genes, particularly those
involved in metabolic and synaptic machinery (Berchtold et al.,
2013; Counts et al., 2013). Future research is necessary to
confirm these findings in other AD cohorts, clarify whether
the cumulative effect of these expression patterns is protective
in vivo and by which sirt1-mediated mechanism, and determine
whether augmentation of cell survival pathways such as sirt1
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represents a viable strategy to delay neurodegeneration in
prodromal AD. Linking these concepts to recent advances in
miRNA knockdown and mimetic technology will usher in a
new class of powerful in vitro and in vivo approaches to
test the efficacy of miRNA-based therapies in preclinical AD
models.
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